Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
April 16, 2024Tobacco Induced DiseasesOpen Access

Efficacy of bupropion and varenicline genetic markers in choosing pharmacological treatment for smoking cessation, and implications for combining drugs: A randomized controlled trial (GENTSMOKING)

View Full Paper
Ask AI
Bookmark
Share

Authors

PGPatrícia Viviane GayaJSJuliana Rocha SantosPTPaulo Roberto Xavier Tomaz

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Gaya et al. (2024) studied this question.

synapsesocial.com/papers/68e6ee25b6db64358766958ahttps://doi.org/10.18332/tid/186072
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Effectiveness of Coadministration of Varenicline, Bupropion, and Serotonin Reuptake Inhibitors in a Smoking Cessation Program in the Real-Life Setting2012 · 32 citations
  2. 2Personalizing smoking cessation pharmacotherapy using neuroaffective reactivity profiles: A randomized controlled trial2026
  3. 3Efficacy of varenicline or bupropion and its association with nicotine metabolite ratio among smokers with <scp>COPD</scp>2024 · 4 citations
  4. 4Smoking Cessation After Initial Treatment Failure With Varenicline or Nicotine Replacement2024 · 10 citations
  5. 5Addition of Bupropion or Varenicline to Nicotine Replacement Therapy After Acute Coronary Syndrome: A Propensity-Matched Real-World Analysis2026